20.760 articles found

Levodopa-carbidopa intestinal gel for advanced Parkinson's disease: Impact of LRRK2 and GBA1 mutations.

Thaler A, Anis S, Ponger P, Fay-Karmon T, Livneh V, Faust-Socher A, Greenbaum L, Reiner J, Hilel A, Shabtai H, Alcalay RN, Djaldetti R, Hassin-Baer S, Ezra A, Mirelman A, Giladi N, Gurevich T.

Parkinsonism Relat Disord · 2024-08-28

DOI: 10.1016/j.parkreldis.2024.107115PMID: 39208588

Effect of concomitant use of esomeprazole on levodopa pharmacokinetics and clinical symptoms in patients with Parkinson's disease.

Miyaue N, Yabe H, Nagai M.

J Neurol Sci · 2024-08-28

DOI: 10.1016/j.jns.2024.123202PMID: 39213821

Atypical suicide attempt facilitated by levodopa in a patient with impending Parkinson’s Disease masquerading as a mood disorder: a case report

Mara A, Myriknas S, Tychala S.

European psychiatry : the journal of the Association of European Psychiatrists · 2024-08-27

Dopaminergic neurons lacking Caspase-3 avoid apoptosis but undergo necrosis after MPTP treatment inducing a Galectin-3-dependent selective microglial phagocytic response.

García-Revilla J, Ruiz R, Espinosa-Oliva AM, Santiago M, García-Domínguez I, Camprubí-Ferrer L, Bachiller S, Deierborg T, Joseph B, de Pablos RM, Rodríguez-Gómez JA, Venero JL.

Cell Death Dis · 2024-08-27

DOI: 10.1038/s41419-024-07014-9PMID: 39223107

Does Delaying Levodopa Prevent Motor Complications in Parkinson's Disease? A Meta-Analysis.

Ramanzini LG, Frare JM, Camargo LFM, Silveira JOF, Jankovic J.

Mov Disord Clin Pract · 2024-08-27

DOI: 10.1002/mdc3.14198PMID: 39189097

Improving efficacy of repetitive transcranial magnetic stimulation for treatment of Parkinson disease gait disorders.

Panda R, Deluisi JA, Lee TG, Davis S, Muñoz-Orozco I, Albin RL, Vesia M.

Front Hum Neurosci · 2024-08-26

DOI: 10.3389/fnhum.2024.1445595PMID: 39253068

Subcutaneous foslevodopa in akinetic crisis. A case report from the neurological intensive care unit.

Loeffler MA, Mengel A, Single C, Weiss D, Feil K.

Front Med (Lausanne) · 2024-08-26

DOI: 10.3389/fmed.2024.1446345PMID: 39253538

Unveiling differential gene co-expression networks and its effects on levodopa-induced dyskinesia.

Piedade de Souza T, Santana de Araújo G, Magalhães L, Cavalcante GC, Ribeiro-Dos-Santos A, Sena-Dos-Santos C, Silva CS, Eufraseo GL, de Freitas Escudeiro A, Soares-Souza GB, Santos-Lobato BL, Ribeiro-Dos-Santos Â.

iScience · 2024-08-26

DOI: 10.1016/j.isci.2024.110835PMID: 39297167

Acute Neuroinflammation Alters the Transport of a Model Therapeutic Protein from the Brain into Lymph and Blood.

Hoang TA, Jin L, Nicolazzo JA, Trevaskis NL.

Mol Pharm · 2024-08-26

DOI: 10.1021/acs.molpharmaceut.4c00516PMID: 39185947

Proteomic analysis of substantia nigra reveals molecular insights into the neuroprotection effect of rosmarinic acid treatment in MPTP-induced mouse model of Parkinson's Disease.

Silva SPd, Rodrigues-Ribeiro L, Gorshkov V, Kjeldsen F, Verano-Braga T, Pires R.

· 2024-08-25

DOI: 10.22541/au.172457329.91880912/v1

Cellular senescence: A novel therapeutic target for central nervous system diseases.

Lei SY, Qu Y, Yang YQ, Liu JC, Zhang YF, Zhou SY, He QY, Jin H, Yang Y, Guo ZN.

Biomed Pharmacother · 2024-08-24

DOI: 10.1016/j.biopha.2024.117311PMID: 39182322

Indirect influence on the BDNF/TrkB receptor signaling pathway via GPCRs, an emerging strategy in the treatment of neurodegenerative disorders.

Antonijevic M, Dallemagne P, Rochais C.

Med Res Rev · 2024-08-24

DOI: 10.1002/med.22075PMID: 39180386